Jordan J. Feld - Concepedia

Author

Jordan J. Feld

Also Known As

Elizabeth Keoshkerian, Feld, Jordan J., François MJ Lamoury, Fried, Michael W., J Feld, J J Feld, J. Feld, J. J Feld, J. J. FELD, J. J. Feld

661

Publications

27.3K

Citations

H-Index

151

Concepts

All Affiliations

University of Toronto University Health Network Toronto General Hospital Toronto Liver Centre National Institutes of Health

About

Jordan J. Feld is an author at University of Toronto specializing in medicine, hepatitis, and viral hepatitis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	46	90	7.3K
2	Public Health	16	19	1.3K
3	Health Sciences	7	7	444
4	Engineering	2	2	202
5	Arts	1	1	25

Jordan J. Feld

240

Publications

21K

Citations

H-Index

Page 1

	Year	Citations
Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis Bart J. Veldt, Jordan J. Feld, Heiner Wedemeyer, JAMA	2012	1.5K
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection Jordan J. Feld, Ira M. Jacobson, Christophe Hézode, New England Journal of Medicine	2015	1.1K
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options Ira M. Jacobson, Stuart C. Gordon, Kris V. Kowdley, New England Journal of Medicine	2013	1.1K
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin Jordan J. Feld, Kris V. Kowdley, Eoin Coakley, New England Journal of Medicine	2014	898
Residual NADPH Oxidase and Survival in Chronic Granulomatous Disease Douglas B. Kuhns, W. Gregory Alvord, Theo Heller, New England Journal of Medicine	2010	551
Hepatic Gene Expression Discriminates Responders and Nonresponders in Treatment of Chronic Hepatitis C Viral Infection Limin Chen, Ivan Borozan, Jordan J. Feld, Gastroenterology Autoimmune DiseaseHepatitis CHepatologyViral HepatitisLiver Physiology	2005	451
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection Stefan Zeuzem, Graham R. Foster, Stanley Wang, New England Journal of Medicine	2018	426
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores George N. Ioannou, Lauren A. Beste, Pamela K. Green, Gastroenterology Baseline CirrhosisHcv EradicationHepatologyViral HepatitisMedicine	2019	384
Autoimmune Hepatitis: Effect of Symptoms and Cirrhosis on Natural History and Outcome * Jordan J. Feld, Huong T T Dinh, Tamara Arenovich, Hepatology	2005	365
Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis Rohit Loomba, Glen Lutchman, David E. Kleiner, Alimentary Pharmacology & Therapeutics	2008	296

Page 1